Around the world: Hong Kong CI

Companies continuously try to differentiate their offerings, trying to make their proposition better in some way. Many would argue this has just made the customer’s job of comparing products even harder, and discerning whether or not a newly added disease is a benefit of value is something that is hard to ascertain. RGA’s Critical Illness (CI) Cards put diseases in context, with the likely incidence rates and claim experience being reported. But this is only one of many dimensions on which policies can be compared. Some companies have differentiated themselves based on distribution ch...